secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087259
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance posts Q2 product revenue $31.1M; guides FY24 $160-165M, FY25 $450-475M
------------------------------------------------------------------------------

- Q2 net loss $97.1M ($0.34/shr) vs. $106.5M ($0.47) a year ago; revenue $31.1M from Amtagvi ($12.8M) and Proleukin ($18.3M).
- FY24 product revenue guidance $160-165M; FY25 $450-475M; Q3 2024 expected $53-55M.
- Over 55 patients infused with Amtagvi since April; >50 ATCs in 29 states; >70 ATCs targeted by year-end.
- Cash $449.6M as of July 24, up from $346.3M at Dec 2023, partly from ~$200M ATM equity raise.
- Lifileucel pipeline: frontline melanoma TILVANCE-301 enrolling globally; NSCLC Phase 2 accelerating; endometrial cancer Phase 2 started.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924087259/0001104659-24-087259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924087259/tm2421110d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer